Drug Database
EP

epidermal growth factor receptor (EGFR pharmDx / EGFR pharmDx Kit)

✓ Approved

Dako · EGFR · 辅助诊断

什么是 epidermal growth factor receptor?

epidermal growth factor receptor 是一种辅助诊断,由Dako研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

商品名EGFR pharmDx, EGFR pharmDx Kit
公司Dako
药物类别辅助诊断
分子靶点EGFR
给药途径Others
状态Approved

作用机制

分子靶点

epidermal growth factor receptor 作用于 1 个分子靶点:

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

epidermal growth factor receptor 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedItalian journal of dermatology and venereology2026-11-17

Cutaneous and systemic treatment-related adverse events as prognostic markers in immunotherapy and targeted therapy, with a focus on melanoma.

Crespi Orsola O, Santaniello Umberto U, Rosset François F, Pala Valentina V et al.

Immune checkpoint inhibitors (ICIs) and targeted therapies have transformed the management of advanced malignancies but are associated with characteristic adverse events (AEs), many of which are skin-predominant. Increasing evidence indicates that selected treatment-related AEs, particularly immune-related adverse events (irAEs) and on-target toxicities, may serve as dynamic biomarkers of antitumor activity. This review summarizes current data on the incidence, spectrum, and prognostic significance of irAEs and targeted-therapy AEs, with a specific emphasis on cutaneous events relevant to dermatologists. We highlight the robust association between cutaneous irAEs (cirAEs) - including vitiligo, regression of melanocytic nevi and halo phenomena in melanoma - and improved clinical outcomes. We also examine prognostic data for other cutaneous patterns (lichenoid, psoriasiform, bullous), endocrine and other organ-specific irAEs, and on-target dermatologic toxicities under epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR), and BRAF/MEK inhibition. Finally, we discuss mechanistic hypotheses and practical implications for dermatology practice, stressing the need to balance recognition of toxicity as a favorable biomarker with timely management to avoid treatment interruption.

PMID 43043303
阅读全文 →
PubMedFrontiers in oncology2026-11-17

Investigation of the ABO gene as a biomarker in breast invasive carcinoma using cancer profiling and blood type distribution.

Meng Weiwei W, He Jing J, Du Dan D, Zhang Junhua J et al.

Invasive breast carcinoma (BRCA) is one of the leading causes of cancer‑related mortality in women worldwide, highlighting the urgent need for novel prognostic biomarkers. The ABO gene has recently been implicated in various cancers. This study comprehensively investigated the expression pattern, clinical significance, and potential molecular mechanisms of ABO in BRCA. Multi‑omics data from The Cancer Genome Atlas and Genotype‑Tissue Expression databases were utilized. Human breast cancer tissue samples and matched adjacent normal tissue samples were obtained from patients who did not receive preoperative chemotherapy or radiotherapy at the First Affiliated Hospital of Zhengzhou University; non‑tumor specimens were also collected. We delineated the expression profile of the ABO gene in breast cancer tissues compared with normal breast tissues and across different molecular subtypes. We further evaluated its diagnostic utility and prognostic significance, and explored potential molecular mechanisms underlying ABO‑associated phenotypes as well as the distribution of ABO blood types. Quantitative reverse transcription polymerase chain reaction was performed on an independent clinical cohort (n=49 pairs) for validation. ABO expression was significantly downregulated in BRCA tissues compared with normal breast tissues. This low expression was associated with aggressive clinicopathological features, including human epidermal growth factor receptor 2‑positive status, estrogen receptor/progesterone receptor negativity, specific racial backgrounds, and basal‑like molecular subtypes. Functionally, ABO expression demonstrated substantial diagnostic value (area under the curve=0.812) and served as an independent prognostic factor for poor overall survival, disease‑specific survival, and progression‑free interval, although it showed limited predictive accuracy for 1‑, 3‑, and 5‑year survival rates. Mechanistically, gene set enrichment analysis linked low ABO expression to pathways involved in DNA replication and mitochondrial translation, and promoter hypermethylation may act as a potential regulatory mechanism underlying its downregulation. Reduced ABO expression in BRCA was validated in our independent clinical cohort. The ABO gene may serve as a novel diagnostic biomarker in BRCA. Its downregulation is potentially driven by epigenetic silencing and is linked to tumor proliferation and metabolism.

PMID 43041272
阅读全文 →
PubMedArchives of pathology & laboratory medicine2026-11-17

Human Epidermal Growth Factor Receptor 2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma: Guideline Update From the College of American Pathologists in Collaboration With the American Society for Clinical Pathology.

Bartley Angela N AN, Ajani Jaffer A JA, Bridge Julia A JA, Brownlee Amy J AJ et al.

With advances in treatment options and clinical trials for patients with advanced gastroesophageal adenocarcinoma (GEA), human epidermal growth factor receptor 2 (HER2, ERBB2 [erb-b2 receptor tyrosine kinase 2]) testing in GEA continues to evolve. To assess evidence published since the 2016 College of American Pathologists (CAP)/American Society for Clinical Pathology (ASCP)/American Society of Clinical Oncology (ASCO) HER2 testing in GEA guideline and to update evidence-based recommendations. The CAP convened a panel of experts to update the guideline, following standards established by the National Academy of Medicine for developing trustworthy clinical practice guidelines. The expert panel defined key questions and performed a systematic review of the literature. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, recommendations were updated based on available evidence, certainty of evidence, and key judgments. Three strong recommendations were developed. Of 6 statements from the 2016 CAP-ASCP-ASCO guideline released for public comment, 4 were reaffirmed as good practice statements for the assessment of HER2 in advanced GEA, and 2 were archived. The expert panel recommends that at initial diagnosis of advanced GEA, testing should be performed on the highest-quality tumor specimen. Immunohistochemistry followed by in situ hybridization, if indicated, should be used as the primary assessment for HER2 status. Genomic testing may be used concurrently or subsequently for clinical decision-making. In patients considered for subsequent therapy after disease progression, testing may be performed on relapsed/recurrent tumor. Tissue is preferable but testing may be performed on liquid biopsy.

PMID 43042926
阅读全文 →
PubMedGastroenterology research2026-11-17

Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin.

Shi Xin X, Wang Wei Jun WJ, He Ke Ji KJ, Wang De Chen C et al.

Initially unresectable stage IV gastric cancer is usually treated with systemic therapy. Conversion surgery may be considered in selected patients after a substantial response. Pathological complete response (pCR) in the resected gastric primary and lymph nodes after such treatment is uncommon. We report the case of a 51-year-old male diagnosed with gastric adenocarcinoma (cT3NxM1, clinical stage IV) with synchronous liver metastases. The tumor was human epidermal growth factor receptor 2 (HER2)-positive (3+), proficient in mismatch repair (pMMR), with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of 30. After three cycles of oxaliplatin + S-1 (SOX) combined with cadonilimab, and disitamab vedotin, computed tomography imaging demonstrated marked tumor regression with nearly complete resolution of liver metastases. The patient underwent radical distal gastrectomy with D2 lymphadenectomy. Postoperative pathology revealed tumor regression grade (TRG) 0-a complete pathological response-with all 33 lymph nodes negative for carcinoma and all surgical resection margins clear (R0). Intraoperative ultrasound confirmed no residual liver metastases. This case illustrates complete pathological regression in the examined gastric and nodal specimens after SOX, cadonilimab, and disitamab vedotin, the patient achieved a pathological complete remission after conversion surgery, accompanied by significant radiological regression of liver lesions. However, it also raises a series of questions for further consideration, such as whether conversion surgery can provide additional benefits after achieving deep tumor regression, the safety of combination therapy, and how to select appropriate candidates for surgery.

PMID 43042191
阅读全文 →
PubMedEClinicalMedicine2026-11-17

Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer.

Glaviano Antonino A, Abelman Rachel O RO, Varkaris Andreas A, Varma Samika S et al.

Combination treatment with endocrine therapy and cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors is the standard first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced/metastatic breast cancer. However, mechanisms of resistance to endocrine therapy plus CDK4/6 inhibitors, mostly classified as alterations involving activation of cell cycle mediators or alternative signalling axes such as the PI3K/AKT/mTOR (PAM) pathway, can still occur. These insights underscore the urgency of developing novel combinations that target the oestrogen receptor pathway, cyclin-CDK4/6 network, and PAM pathway, which may circumvent treatment resistance, and improve the therapeutic index in the current era of precision medicine. Approved therapies for hormone receptor-positive, HER2-negative, advanced breast cancer patients include, the PI3K inhibitors, alpelisib and inavolisib for PIK3CA-mutated tumours, the AKT inhibitor, capivasertib for AKT1-, PIK3CA-, or PTEN-altered tumours, and, the mTOR inhibitor, everolimus used irrespective of the mutational status. Given these recently approved drugs, clinicians must now choose between multiple potential therapies for a subset of patients. This Review describes available and emerging targeted therapies for patients with advanced/metastatic, hormone receptor-positive, HER2-negative breast cancer.

PMID 43042018
阅读全文 →
PubMedWorld journal of oncology2026-11-17

CDK4/6 Inhibitors and Endocrine Therapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Real-World Cohort.

Marin-Trigueros Daniel D, Landaverde Denis U DU

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy are standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, but Latin American patients were underrepresented in the pivotal trials, and real-world data from public health systems remain scarce. We aimed to describe the effectiveness and safety of these agents in the Costa Rican public health system and to explore differences between palbociclib and ribociclib. We conducted a retrospective, multicenter cohort study of adults with HR-positive/HER2-negative metastatic breast cancer who started palbociclib or ribociclib plus endocrine therapy in first or later lines of therapy at four hospitals of the Costa Rican Social Security Fund (treatment indicated 2017-2021). Progression-free survival (PFS) and overall survival (OS), measured from CDK4/6 inhibitor initiation, were estimated with the Kaplan-Meier method. The inhibitor comparison was exploratory and was adjusted with a multivariable Cox model with covariates selected a priori and with inverse probability of treatment weighting. Dose reduction was analyzed as a time-dependent covariate and with landmark analyses. Of 234 patients identified, 14 died or progressed before treatment could start; 220 patients were analyzed (palbociclib 65.5%, ribociclib 34.5%; first-line 60.9%). At a median follow-up of 45.1 months, median PFS was 19.4 months and median OS was 29.1 months (first-line: 24.4 and 39.7 months; second or later line: 15.0 and 23.3 months). PFS and OS did not differ significantly between inhibitors (adjusted hazard ratio (HR) for ribociclib versus palbociclib: PFS 0.89, 95% confidence interval (CI) 0.62-1.26; OS 0.92, 95% CI 0.63-1.36). Eastern Cooperative Oncology Group (ECOG) performance status 1 and the second or later line of therapy were independently associated with shorter PFS and OS. Grade 3/4 adverse events were recorded in 20.5% of patients (grade 3/4 neutropenia 18.6%). Dose reduction, required in 15.9% of patients and analyzed as a time-dependent covariate, was not associated with PFS (adjusted HR 1.04, 95% CI 0.67-1.61) or OS (adjusted HR 0.77, 95% CI 0.46-1.30). In this national public-system cohort, CDK4/6 inhibitors were deliverable with a manageable, predominantly hematological toxicity profile. PFS was in the range reported in trials and real-world series, whereas OS was shorter than in the registration trials and in other large real-world cohorts, particularly beyond first line. No significant difference was observed between ribociclib and palbociclib after adjustment, and dose reduction did not appear to compromise effectiveness.

PMID 43042199
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多epidermal growth factor receptor